Matrix metalloproteinases in inflammatory demyelination: Targets for treatment

Neurology

Volumn 53, Issue 1, 1999, Pages 20-25

  Kieseier, Bernd C ^a   Seifert, Thomas ^a   Giovannoni, Gavin ^b   Hartung, Hans Peter ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; GELATINASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN;

BONE REMODELING; DEMYELINATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATORY DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

EID: 0033551546     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.1.20     Document Type: Review

References (49)

1. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol Chem Hoppe-Seyler 1995;376:345-355.
2. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374-17378.
3. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735.
4. Woessner JF Jr. The family of matrix metalloproteinases. Ann NY Acad Sci 1994;732:11-21.
5. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature 1994;370:555-557.
6. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 1994;370:218-220.
7. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumor necrosis factor-α from cells. Nature 1997;385:729-733.
8. Gray RD, Paterson CA. Application of peptide-based matrix metalloproteinase inhibitors in corneal ulceration. Ann NY Acad Sci 1994;732:206-216.
9. Cawson T. Matrix metalloproteinases and TIMPs: properties and implications for rheumatic diseases. Mol Med Today 1998; 4:130-137.
10. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-4728.
11. Yong VW, Krekowski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21:75-80.
12. Raine CS. Demyelinating diseases. In: Davis RL, Robertson DM, eds. Textbook of neuropathology. Baltimore: Williams & Wilkins, 1992:535-552.
13. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994;15:1165-1178.
14. Hartung H-P, Jung S, Stoll G, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992;40:197-210.
15. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998;152:729-741.
16. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
17. Nielsen BS, Timshel S, Kjeldsen L, et al. 92kDa Type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 1996;65:57-62.
18. Cuzner ML, Gveric D, Strand C, et al. The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996;55:1194-1204.
19. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309.
20. Gijbels K, Proost P, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993;36:432-440.
21. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-166.
22. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576:203-207.
23. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WA. Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 1994;71:417-422.
24. Anthony DC, Miller KM, Fearn S, et al. Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998;87: 62-72.
25. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223-226.
26. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993;192:1175-1181.
27. Clements JM, Cossins JA, Wells GMA, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumor necrosis factor-α inhibitor. J Neuroimmunol 1997; 74:85-94.
28. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994;94:2177-2182.
29. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 1995;44:345-349.
30. Matyszak MK, Perry VH. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J Neuroimmunol 1996;69: 141-149.
31. Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 1998;44:35-46.
32. Raine CS. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 1994;36: S61-S72.
33. Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 1978;4:337-344.
34. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
35. Cannella B, Raine SC. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37: 424-435.
36. Pearl GS, Mullins RE. α1-Antitrypsin in cerebrospinal fluid of patients with neurologie diseases. Arch Neurol 1985;42: 775-777.
37. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-barrier barrier injury. Neurology 1996;46:1626-1632.
38. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is electively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998;121:2327-2334.
39. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain 1999; 122:191-197.
40. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
41. Leppert D, Waubant E, Bürk MR, Oksenberg JR, Hauser SL. Interferon beta-lb inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40: 846-852.
42. Stüve O, Dooley NP, Uhm JH, et al. Interferon β-1b decreases the migration of T lymphocytes in vitro: effects on matrix-metalloproteinase-9. Ann Neurol 1996;40:853-863.
43. Arnason BGW, Soliven B. Acute inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo J, eds. Peripheral neuropathy. Philadelphia: WB Saunders, 1993:1437-1497.
44. Kieseier BC, Clements JM, Pischel HB, et al. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-434.
45. Hughes PM, Wells GMA, Clements JM, et al. Matrix metalloproteinase expression during experimental autoimmune neuritis. Brain 1998;121:481-494.
46. Redford EJ, Smith KJ, Gregson NA, et al. A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. Brain 1997;120:1895-1905.
47. Hartung HP. Pathogenesis of inflammatory demyelination: implications for therapy. Curr Opin Neurol 1995;8:191-199.
48. Créange A, Lerat H, Meyrignac C, Degos J-D, Gherardi RK, Cesaro P. Treatment of Guillain-Barré syndrome with interferon-β. Lancet 1998;352:368-369.
49. Yong YW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis. Neurology 1998;51: 682-689.